Due to the peptide compositions, AMPs are unfortunately limited in their potential to be used in vivo by a number of variables, including minimal tissue penetration, rapid removal from circulation, decreased bioavailability, limited stability, and low selectivity against bacterial cells relative to mammalian cells
The synergy argument is therefore mechanistic extrapolation reasoning from what each does separately to what they might do together
Beyond actin binding, TB 500 research has documented roles in: Angiogenesis promoting blood vessel growth through endothelial cell migration Anti-inflammatory modulation reducing pro-inflammatory cytokines in wound environments Cardiac tissue repair a significant area of T4 research, particularly in post-ischemia models Stem cell activation potential to mobilize progenitor cells toward injured sites Neuronal repair observed neuroprotective effects in spinal and brain injury models Researchers interested in the cardiac and systemic repair dimensions of TB 500 often cross-reference their findings with work on growth hormone-releasing peptides like Tesamorelin and Sermorelin, given shared downstream interest in tissue anabolism and metabolic regulation
Reasoning: This was a highly significant switch in 2017
Soft tissues respond faster
My other problem is I get a LOT of yeast infections